GlassScriptPhysician profile
Wendi Ellen Ames
NPI 1033725718
$3,997.78
in general payments reported to CMS, 2019-2025
37 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $256 · 2023: $59.85 · 2024: $1,601 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.66 | 2023-2025 | |
| Neurelis, INC. | $360.73 | 2024-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $264.78 | 2022-2024 | Qelbree |
| Lundbeck LLC | $238.01 | 2022-2025 | Vyepti, Rexulti |
| Mallinckrodt Hospital Products INC. | $187.44 | 2024-2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $176.71 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $174.89 | 2024-2025 | |
| Eisai INC. | $160.85 | 2024-2025 | |
| Ucb, INC. | $140.40 | 2024 | Fintepla, Nayzilam |
| Neurocrine Biosciences, INC. | $129.90 | 2021-2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $127.90 | 2024-2025 | |
| Incyte Corporation | $126.77 | 2024-2025 | Jakafi, Monjuvi, Niktimvo |
| Astrazeneca Pharmaceuticals LP | $122.02 | 2024-2025 | Calquence, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $116.28 | 2021-2022 | |
| Pfizer INC. | $114.69 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.57 | 2022 | |
| Sk Life Science, INC. | $75.26 | 2025 | |
| Acadia Pharmaceuticals INC | $74.96 | 2025 | Nuplazid |
| Biogen, INC. | $74.75 | 2024 | Vumerity, Tysabri, Avonex |
| Inspire Medical Systems, INC. | $71.04 | 2025 | Inspire |
| Kyowa Kirin, INC. | $55.06 | 2024-2025 | Nourianz |
| Springworks Therapeutics, INC. | $54.45 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $44.46 | 2024-2025 | Ultomiris |
| Axsome Therapeutics, INC. | $44.41 | 2025 | Symbravo |
| Novo Nordisk INC | $33.33 | 2022-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $32.59 | 2021-2025 | Amyvid, Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $28.39 | 2024 | Hyqvia |
| Gilead Sciences, INC. | $27.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $24.90 | 2025 | Givlaari |
| Argenx US, INC. | $23.97 | 2024 | Vyvgart Hytrulo |
| Emd Serono, INC. | $19.76 | 2021 | |
| Indivior INC. | $17.03 | 2022 | |
| Puma Biotechnology, INC. | $16.41 | 2024 | |
| Merz Pharmaceuticals, LLC | $15.87 | 2025 | Xeomin |
| Biotronik Nro, INC. | $15.64 | 2025 | Prospera |
| Amneal Pharmaceuticals LLC | $15.09 | 2024 | Crexont |
| Daiichi Sankyo INC. | $13.19 | 2024 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendi Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.